

PII: S0040-4020(97)10063-1

# Syntheses of 2,6-Anhydro-3-deoxy-5-O-phosphono-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonic Acid, Its Dimeric Analogue, and Related Compounds

Masao Shiozaki,\*a Shin-ichi Kurakata,<sup>b</sup> Tohru Tatsuta,<sup>b</sup> Hiroaki Maeda,<sup>b</sup> and Masahiro Nishijima<sup>C</sup>

 <sup>a</sup> Exploratory Chemistry Research Laboratories, Sankyo Co. Ltd.
<sup>b</sup> Biological Research Laboratories, Sankyo Co. Ltd.
Hiromachi 1-2-58, Shinagawa-ku, Tokyo 140, Japan
<sup>c</sup> Department of Biochemistry and Cell Biology, National Institute of Health, Toyama 1-23-1, Shinjuku-ku, Tokyo 162, Japan

Abstract: Pyran carboxylic acid analogues of GLA-60 (12a, 12b, and 17) and their dimeric analogues (21 and 24) were synthesized in a stereocontrolled manner. Compounds 12a and 17 showed endotoxin antagonistic activity toward human monoblastic U937 cells as an index of the inhibition of LPS-induced TNF $\alpha$  production. Compounds 12b and 24 were less active than 12a and 17. Dimeric ester 21 was practically inactive. © 1997 Elsevier Science Ltd.

## Introduction

Lipopolysaccharides  $(LPS)^1$  cover the outer surface membrane of such Gram-negative bacteria as Salmonella minnesota, Salmonella typhimurium, and Escherichia coli, and are highly potent stimulators of the immune system. A variety of responses, both beneficial and harmful, can be elicited by LPS. One of these harmful responses is fatal endotoxic shock (bacterial sepsis) caused as a consequence of acute inflammatory response, which has precluded the clinical use of LPS. Most of the biological activities of LPS reside in a relatively small portion of the molecule, that is, the terminal disaccharide phospholipid subunit known as lipid A,<sup>2</sup> which is a hydrophobic anchor substance holding an essentially linear polysaccharide chain to the cell wall. Lipid A was chemically synthesized by both Shiba et al. and Achiwa et al.<sup>3</sup>

In a series of investigations by Hasegawa and Kiso<sup>4</sup> on the relationship between the molecular structure and biological activity of non-reducing sugar subunit analogues of lipid A, it has been demonstrated that several kinds of biological activities of LPS can be expressed by certain 4-O-phosphono-D-glucosamine derivatives such as GLA-60.<sup>4</sup> Recently, Qureshi's group<sup>5</sup> has isolated a lipid A-related compound from *Rhodobacter sphaeroides* as an inseparable mixture of three compounds, which showed potent LPS antagonist activity. Furthermore, an Eisai group has developed a related compound, E-5531,<sup>6</sup> as a highly potent anti-septicemia drug.

In early studies, endotoxin and its related compounds were investigated for their potential as anti-cancer medicines that function as LPS-agonists by activating macrophages. However, in recent years, endotoxinrelated compounds have been studied as LPS-antagonists, which may be useful in treating inflammation, autoimmune diseases or septicemia, by deactivating LPS-induced aggressive macrophages.

During our investigation of the biological activity of compounds related to GLA-60, we found that most of them had LPS-agonistic activity, but a few of them behaved as LPS antagonists. Among them, carboxymethyl 2-deoxy-2-(2,2-difluorotetradecanamido)-4-O-phosphono-3-O-[(R)-3-(tetradecanoyloxy)tetra-decanoyl]- $\alpha$ -D-glucopyranoside exhibited fairly strong LPS antagonistic activity.<sup>7</sup> By analogy, we designed pyran carboxylic acids (**12a** and **12b**) as related LPS-antagonists. In this paper, we would like to describe the synthesis of 2,6-anhydro-3-deoxy-5-O-phosphono-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonic acid (**12a**),<sup>8</sup> some related compounds (**12b** and **17**) and its dimeric analogues (**21** and **24**).

#### Synthesis


1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-D-glucopyranoside, obtained from D-glucosamine hydrochloride using the method reported by Vasella,<sup>9</sup> was converted to 3,4,6-tri-O-acetyl-2-azido-2-deoxy-D-glucopyranoside according to Excoffier's procedure, <sup>10</sup> and then further converted to a mixture of  $\alpha$ - and  $\beta$ -trichloroacetimidates (1).<sup>11</sup> The mixture was partially separated by silica gel chromatography into 1- $\alpha$  (mp. 130-131 °C) and 1- $\beta$ (mp. 136-137 °C). The next stage is the most critical step in the synthesis, because an  $\alpha$ -oriented carboxylic acid equivalent is needed. Schmidt's group<sup>11</sup> has already reported that treatment of 3,4,6-tri-O-benzyl-2-azido-2-deoxy- $\alpha$ -D-glucopyranosyl trichloroacetimidate with trimethylsilyl cyanide using trimethylsilyl trifluoromethane-sulfonate as a catalyst yielded a corresponding  $\alpha$ -cyanide (anometic J=5.4 Hz). Application of this reaction to compound 1- $\alpha$  gave an  $\alpha$ -cyanide 2 as expected. Moreover, application of this reaction to 1- $\beta$ exclusively formed 2. Also, the mixture of  $1-\alpha$  and  $1-\beta$  gave 2 stereospecifically in quantitative yield. Deacetylation of 2 with a catalytic amount of KOH in EtOH, and isopropylidene formation between C5-OH and C7-OH with 2,2-dimethoxypropane using p-TsOH as a catalyst formed 3 (mp. 172-173 °C). The NMR coupling constant between C2-H (anomeric position,  $\delta$  4.94) and C3-H ( $\delta$  3.95) of 2 was J=6.0 Hz, which was a little bit larger than that of the tri-benzyl analogue. However, the  $\alpha$ -cyano configuration of 3 was confirmed from observation of the NOE between C2-H (anomeric position,  $\delta$  4.83) and C3-H ( $\delta$  3.73) of 3. Treatment of 3 in THF with (i) PPh<sub>3</sub> and H<sub>2</sub>O, (ii) tetradecanoic acid or (R)-3-(benzyloxy)tetradecanoic acid, DCC and DMAP, and (iii) tetradecanoyl chloride or (R)-3-(benzyloxy)tetradecanoyl chloride and Et3N yielded 4a (mp. 59-61 °C) or 4b, respectively.

An alternative stepwise treatment of 3 with (i) PPh<sub>3</sub> and NH<sub>4</sub>OH-H<sub>2</sub>O, (ii) 1 equivalent each of tetradecanoic acid or (R)-3-(benzyloxy)tetradecanoic acid and DCC gave 13a or 13b, respectively.


Hydrolysis of both nitriles 4a and 13a with 4M HCl in dioxane-H<sub>2</sub>O (v/v, 10:1), and successive esterification of the resulting carboxylic acid with Ph<sub>2</sub>CN<sub>2</sub> gave a diphenylmethyl ester 5a (mp. 176-179 °C). Also, the same treatment of nitriles 4b and 13b yielded a diphenylmethyl ester 5b.

Isopropylidene formation between C5-OH and C7-OH of 5a or 5b with 2,2-dimethoxypropane using p-

Scheme 1




Reagents and Conditions: a) TMSCN, cat. TMSOTf, 24 °C, 15 h, CH<sub>2</sub>Cl<sub>2</sub>, quantitative; b) (i) cat. KOH, EtOH, 24 °C, 30 min; (ii) Me<sub>2</sub>C(OMe)<sub>2</sub>, cat. p-TsOH·H<sub>2</sub>O, 24 °C, 16 h, DMF, 65%; c) (i) Ph<sub>3</sub>P, THF-H<sub>2</sub>O, 24 °C, 16 h; (ii) tetradecanoic acid or (*R*)-3-(benzyloxy)tetradecanoic acid, DCC, DMAP, 24 °C, 3 h, THF; (iii) tetradecanoyl chloride or (*R*)-3-(benzyloxy)tetradecanoyl chloride, Et<sub>3</sub>N, 24 °C, 16 h, THF, 43% (4a), 85% (4b); d) (i) 4M HCl in dioxane-H2O (10:1), 55-60 °C, 4 h; (ii) Ph<sub>2</sub>CN<sub>2</sub>, 55-60 °C, 1.5 h, DMF, 53% (5a), 33% (5b); e) Me<sub>2</sub>C(OMe)<sub>2</sub>, cat. p-TsOH·H<sub>2</sub>O, 25 °C, 16 h, DMF, 56% (6a), 83% (6b); f) (*R*)-3-(tetradecanoyloxy)tetradecanoic acid, DCC, DMAP, 24 °C, 16 h, CH<sub>2</sub>Cl<sub>2</sub>, 96% (7a), 86% (7b); g) aq. 85% AcOH, 70-75 °C, 1 h, 58% (8a), 37% (8b); h) ClCOOBn, pyridine, 0-5 °C, 30 min, CH<sub>2</sub>Cl<sub>2</sub>, 97% (9a), 97% (9b); i) ClP(O)(OPh)<sub>2</sub>, DMAP, 24 °C, 4 h, CH<sub>2</sub>Cl<sub>2</sub>, 87% (10a), 91% (10b); j) H<sub>2</sub>, Pd/C, 25 °C, 10 h, THF, 89% (11a), 75% (11b); k) H<sub>2</sub>, PtO<sub>2</sub>, 25 °C, 3-10 h, THF, 92% (12a), 96% (12b).



Reagents and Conditions: a) (i)  $Ph_3P$ , THF, 24 °C, 1 h; then 28%  $NH_4OH-H_2O$  (1:3), 24 °C, 16 h; (ii) tetradecanoic acid or (R)-3-(benzyloxy)tetradecanoic acid, DCC, DMAP, 24 °C, 16 h, THF, 82% (13a), 49% (13b); (b) 4M HCl in dioxane- $H_2O$  (10:1), 55-60 °C, 4 h; (ii)  $Ph_2CN_2$ , 55-60 °C, 4 h, DMF, 61% (5a), 41% (5b).

Scheme 3




Reagents and Conditions: a) (i)  $H_2$ , Pd/C, 24 °C, 10 h, THF; (ii)  $Ph_2CN_2$ , 24 °C, 16 h, THF, two steps quantitative; b) DAST, 0-5 °C, 3 h, CH<sub>2</sub>Cl<sub>2</sub>, 87%; c)  $H_2$ , Pd/C, 24 °C, 16 h, THF, 65%; (d)  $H_2$ , PtO<sub>2</sub>, 24 °C, 17 h, THF, quantitative.


TsOH as a catalyst gave 6a (mp. 113-115 °C) or 6b, respectively. Esterification of 6a or 6b with (R)-3-(tetradecanoyloxy)tetra-decanoic acid, DCC and DMAP formed 7a or 7b, respectively. Deprotection of acetonide 7a or 7b with aqueous 85% AcOH gave 8a (mp. 105-106 °C) or 8b, respectively. Treatment of 8a or 8b with benzyl chloroformate and pyridine yielded 9a or 9b, respectively. Treatment of 9a or 9b with diphenyl chlorophosphate and DMAP formed 10a or 10b, respectively. Hydrogenolysis of 10a and 10b using 10% Pd/C as a catalyst gave 11a or 11b, respectively. Finally, hydrogenolysis of 11a or 11b gave 12a or 12b, respectively.

The synthesis of 6-fluorinated compound 17 was accomplished as follows. The diphenylmethyl ester of 1-carboxylic acid and the 7-benzyloxycarbonyl protective group of the hydroxy part in 10a were deprotected by hydrogenolysis, and the resulting carboxylic acid was reprotected with Ph<sub>2</sub>CN<sub>2</sub> to give 14. The hydroxy group at the C7 position of 14 was fluorinated with diethylaminosulfur trifluoride (DAST) to give 15. Deprotection of the diphenylmethyl ester of 15 by hydrogenolysis gave carboxylic acid 16. The






Reagents and Conditions: a) CF<sub>3</sub>COOH, CH<sub>2</sub>Cl<sub>2</sub>, 24 °C, 1 h, 56%; b) DCC, DMAP, 24 °C, 16 h, CH<sub>2</sub>Cl<sub>2</sub>, THF, **19** (11%), **19**' (22%); c) H<sub>2</sub>, Pd/C, THF, 24 °C, 6 h, quantitative; d) H<sub>2</sub>, PtO<sub>2</sub>, THF, 24 °C, 16 h, 80%.



Reagents and Conditions: a) DCC, DMAP, 24 °C, 16 h, CH<sub>2</sub>Cl<sub>2</sub>, THF, 11%; b) H<sub>2</sub>, Pd/C, THF, 24 °C, 6 h; c) H<sub>2</sub>, PtO<sub>2</sub>, THF, 24 °C, 16 h, two steps quantitative.





TPA-treated U937 cells were stimulated with 10 ng/mL of LPS in the presence of the indicated concentrations of the isomers or prednisolone (Pred.) at 1  $\mu$ M. After incubation for 4.5 h, the amounts of TNF $\alpha$  in the culture supernatant were measured by ELISA. As a control, the amount of TNF $\alpha$  produced by U937 cells, which were stimulated with LPS alone, was used. The relative amounts of TNF $\alpha$  produced by U937 cells produced by U937 cells were indicated as percentages of the control.

diphenylphosphono group of 16 was converted to phosphono compound 17 by hydrogenolysis using PtO<sub>2</sub> as a catalyst.<sup>12</sup>

Dimeric compounds 21 and 24 were synthesized as follows. Treatment of diphenylmethyl ester 10a with trifluoroacetic acid gave carboxylic acid 18. Esterification of 18 with 5,7-diol 8a using dicyclohexylcarbodiimide (DCC) as a condensing agent and 4-dimethylaminopyridine (DMAP) as a catalyst gave dimeric ester 19 in 11% yield and urea 19', which was obtained by the side-reaction of carboxylic acid 18 with DCC. The detected dimer was an ester with a primary C7-OH. However, the yield was very low. The same tendency was observed in the reaction of 8a with 16 to form fluorinated dimer 22 in 11% yield. Compounds 19 and 22 were converted to carboxylic acids 20 and 23 by hydrogenolysis using Pd on carbon as a catalyst. Finally, compounds 20 and 23 were further converted to phosphono compounds 21 and 24, respectively, by hydrogenolysis using PtO2 as a catalyst.

#### **Biological Activity**

The inhibitory activities of compounds on LPS-induced TNF $\alpha$  production were investigated *in vitro*, using human monoblastic U937 cells. As shown in Fig. A and B, all five compounds inhibited the LPS-induced TNF $\alpha$  production dose-dependently. The concentrations ( $\mu$ M) of compounds **12a**, **12b**, **17**, **21**, and **24** required to inhibit the LPS-induced TNF $\alpha$  production by U937 cells by 50% (IC50) were 0.0079, 0.065, 0.0057, 3.1, and 0.078, respectively. Prednisolone (an antiinflammatory steroid known to potently inhibit TNF $\alpha$  production by stimulated monocytes)<sup>13</sup> used as a positive control reagent, inhibited the TNF $\alpha$  production by U937 cells by over 90%. None of these compounds showed agonistic activities on the TNF $\alpha$  production (data not shown). These compounds did not exhibit cytotoxic effects on U937 cells at the concentrations used in this study (data not shown).

#### **Experimental Section**

Melting points were uncorrected. 270 MHz <sup>1</sup>H-NMR spectra were recorded using tetramethylsilane as an internal reference. IR absorption spectra were recorded on a Jasco IR A-2 spectophotometer, and mass spectra were obtained with a JMS-O1SG mass spectrometer. Elemental analyses were performed by the Institute of Science and Technology, Inc. Separation of the compounds by column chromatography was carried out with Silica Gel 60 (Merck, 230-400 mesh ASTM) at slightly elevated pressure (1.2-1.5 atom) for easy elution, and the quantity of the used silica gel was 50-100 times the weight of the product purified. Analytical chromatography was performed on Merck Art 5715 silica gel 60-F254 plates.

## 2,6-Anhydro-3-azido-3-deoxy-4,5,7-tri-O-acetyl-D-glycero-D-ido-heptononitrile (2).

To a solution of  $\alpha$ - or  $\beta$ -imidate, or a mixture of  $\alpha$ - and  $\beta$ -imidates (1, 8.44g, 17.7 mmol), and trimethylsilyl cyanide (2.83 mL, 21.3 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (84 mL) was added trimethylsilyl trifluoromethanesulfonate (130 mg) at 24 °C with stirring. After stirring for 3-15 h at room temperature, the solution was concentrated in vacuo to one third the volume, and diluted with EtOAc. The solution was washed with aqueous NaHCO<sub>3</sub> and brine, dried over MgSO<sub>4</sub>, and filtered. The filtrate was concentrated in vacuo, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (2:1) gave 2 (6.22 g, quantitatively)

as a viscous oil. IR  $\nu_{max}$ (film) 2200 (w), 2130, 1750, 1600 (w) cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  2.06 (3H, s), 2.09 (3H, s), 2.12 (3H, s), 3.95 (1H, dd, J=6.0, 10.5 Hz), 4.07-4.19 (2H, m), 4.30-4.38 (1H, m), 4.94 (1H, d, J=6.0 Hz), 5.01-5.11 (1H, m), 5.34-5.44 (1H, m); MS (FAB, positive) *m/z* 341 (M+H)<sup>+</sup>. Anal. Calcd. for C<sub>13</sub>H<sub>16</sub>N<sub>4</sub>O<sub>7</sub> (340.3): C, 45.87; H, 4.74; N, 16.47. Found: C, 45.75; H, 4.31; N, 16.22.

## 2,6-Anhydro-3-azido-3-deoxy-5,7-O-isopropylidene-D-glycero-D-ido-heptononitrile

(3). To a solution of 2 (5.36 g, 15.8 mmol in EtOH, 200 mL) was added KOH (290 mg, 5.2 mmol). After stirring for 30 min at 24 °C, the solution was concentrated in vacuo to give a residue which was dissolved in DMF (36 mL) and 2,2-dimethoxypropane (36 mL). To this solution, *p*-TsOH·H<sub>2</sub>O (1.44 g, 7.6 mmol) was added, and the mixture was stirred for 16 h at 25 °C, diluted with EtOAc, which was washed with aqueous NaHCO3 and brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (2:1) gave 3, (2.60 g, 65% yield) as a solid, mp 172-173 °C (from EtOAc-hexane). IR v<sub>max</sub>(Nujol) 3510, 2230 (w), 2130 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  1.45 (3H, s), 1.51 (3H, s), 2.98 (1H, bs, OH), 3.50-3.60 (1H, m), 3.65-3.80 (3H, m), 3.84-4.07 (2H, m), 4.83 (1H, d, *J*=5.9 Hz, C2-H. NOE was observed between the protons, C3-H ( $\delta$  3.73) and C2-H. Therefore, the configuration at C2 position is *S*, and the nitrile group is *axial*.); MS (FAB, positive) *m*/z 255 (M+H)<sup>+</sup>, 239. *Anal*. Calcd. for C<sub>10</sub>H<sub>14</sub>N<sub>4</sub>O<sub>4</sub> (254.2): C, 47.24; H, 5.55; N, 22.04. Found: C, 47.29; H, 5.52; N, 22.20.

2,6-Anhydro-3-deoxy-5,7-O-isopropylidene-3-tetradecanamido-4-O-tetradecanoyl-D-To a solution of 3 (2.21 g, 8.84 mmol) in THF (80 mL) was glycero-D-ido-heptononitrile (4a). added Ph3P (4.37 g, 16.68mmol). After stirring for 3 h at 24 °C, H2O (8.0 mL) was added to this solution. The mixture was stirred for 16 h at 24 °C, and concentrated in vacuo to give a mixture which was dried with a pump. The mixture was dissolved in THF (80 mL). To this solution, tetradecanoic acid (2.00 g, 8.76 mmol), DCC (1.81 g, 8.76 mmol), and DMAP (1.07 g, 8.76 mmol) were added with stirring at 24 °C. Furthermore, after 3 h stirring at 24 °C, to this reaction mixture, tetradecanoyl chloride (2.16 g, 8.76 mmol) and Et3N (1.68 g, 16.68 mmol) were added. The stirring was continued for 16 h at 24 °C. The reaction mixture was diluted with EtOAc, which was washed with H2O, aqueous NaHCO3, and brine, dried over MgSO4, filtered, and concentrated in vacuo to give a mixture. The mixture was chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (9:1, then 4:1) gave 4a (2.33 g, 43% yield) as an amorphous solid, mp 59-61 °C (from iso-Pr<sub>2</sub>O). IR v<sub>max</sub>(Nujol) 3420, 3360, 1727, 1670, 1655 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.88 (6H, t, J=6.2-7.0 Hz), 1.26 (40H, bs), 1.40 (3H, s), 1.49 (3H, s), 1.50-2.02 (5H, m), 2.18 (1H, m), 2.30-2.45 (2H, m), 3.70-3.80 (3H, m), 3.96 (1H, m), 4.24 (1H, m), 5.11 (1H, m), 5.14 (1H, d, J=6.3 Hz), 6.27 (1H, d, J=6.9 Hz, NH); MS (EI) m/z 648 (M<sup>+</sup>), 633 (M<sup>+</sup>-Me); MS (FAB, positive) m/z 671 (M+Na)<sup>+</sup>, 649 (M+H)+; High Resolution MS (FAB, positive), Calcd. for C38H68N2O6Na: 671.4975. Found: 671.4955, and Calcd. for C38H68N2O6: 649.5156. Found: 649.5165. Anal. Calcd. for C38H68N2O6 (648.9): C, 70.33; H, 10.56; N, 4.32. Found: C, 70.57; H, 10.66; N, 4.69.

2,6-Anhydro-3-deoxy-5,7-O-isopropylidene-3-tetradecanamido-D-glycero-D-ido-heptononitrile (13a).To a solution of 3 (127 mg, 0.50 mmol) in THF (5 mL) was added PPh3(328 mg, 1.25 mmol).After stirring for 1 h at 24 °C, H2O (0.3 ml) and 28% NH4OH (0.1 ml) were added.

The mixture was stirred for 16 h at 24 °C. The reaction mixture was concentrated in vacuo, and diluted with EtOAc, and then concentrated in vacuo to give a mixture. The residual mixture was diluted with THF (5 ml), and tetradecanoic acid (137 mg, 0.60 mmol) and DCC (124 mg, 0.60 mmol) were added. After stirring for 16 h, the mixture was filtered, concentrated, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (1:1) gave 13a (179 mg, 82%) as a gum. IR  $v_{max}$ (KBr) 3430, 3327, 2925, 2853, 1650, 1627 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (3H, t, J=6.4-6.8 Hz), 1.25 (20H, bs), 1.45 (3H, s), 1.52 (3H, s), 1.59-1.69 (2H, m), 2.26 (2H, t, J=7.3-7.9 Hz), 2.79 (1H, d, J=2.3 Hz, OH), 3.55-3.96 (5H, m), 4.14 (1H, m), 5.28 (1H, d, J=5.9 Hz, C2-H), 5.94 (1H, d, J=5.6 Hz, NH); MS (FAB, positive) *m/z* 439 (M+H)<sup>+</sup>; High Resolution MS (FAB, positive), Calcd. for C24H43N2O5: 439.3172. Found: 439.3171

**Diphenylmethyl 2,6-Anhydro-3-deoxy-3-tetradecanamido-D**-glycero-D-ido-heptonate (5a). (a) To a solution of 4a (2.31 g, 3.56 mmol) in dioxane (18 mL), 4M HCl in dioxane (18 mL) and H<sub>2</sub>O (1.8 mL) were added. The solution was warmed at 55-60 °C for 4 h. The reaction mixture was concentrated, and dried in vacuo to give a mixture which was dissolved in DMF (20 mL). Ph<sub>2</sub>CN<sub>2</sub> (2.5 g) was added to this solution, which was warmed at 55-60 °C for 1.5 h, concentrated in vacuo, and chromatographed on a silica gel column. Elution with EtOAc, then 5% MeOH in EtOAc gave 5a (1.11 g, 53% yield) as a solid, mp 176-179 °C (from EtOAc). IR  $v_{max}$ (Nujol) 3325 (broad), 2470, 2420, 1733, 1637 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMF-d7)  $\delta$  0.88 (3H, t, J=6.4-6.8 Hz), 1.27 (20H, bs), 1.43-1.52 (2H, m), 1.94-2.11 (2H, m), 3.44 (1H, m), 3.60-3.80 (3H, m), 3.80-3.92 (1H, m), 3.92-4.07 (1H, m), 5.20 (1H, d, J=4.9 Hz, OH), 6.88 (1H, s), 7.27-7.49 (10H, m), 7.60 (1H, d, J=7.3 Hz, NH); MS m/z 583 (M<sup>+</sup>). Anal. Calcd. for C34H49NO7 (583.7): C, 69.96; H, 8.46; N, 2.40. Found: C, 69.71; H, 8.80; N, 2.81.

(b) A solution of **13a** (154 mg, 0.264 mmol) in dioxane (1.5 ml), 4M HCl-dioxane (1.5 mL) and H<sub>2</sub>O (0.15 mL) was warmed at 55-60 °C for 2 h, and this reaction mixture was concentrated in vacuo, then diluted with EtOAc, and concentrated to dryness. This procedure was repeated two more time, and the resulting material was dried in vacuo, and then dissolved in DMF (2 mL). To this mixture, Ph<sub>2</sub>CN<sub>2</sub> (230 mg, ) was added, and warmed at 55-60 °C for 2 h. The reaction mixture was concentrated in vacuo, and chromatographed on a silica gel column. Elution with EtOAc, and then 5% MeOH in EtOAc gave **5a** (125 mg, 61%) as a solid.

**Diphenylmethyl** 2,6-Anhydro-3-deoxy-5,7-isopropylidene-3-tetradecanamido-Dglycero-D-ido-heptonate (6a). A solution of 5a (1.10 g, 1.88 mmo) in DMF (4 mL) and 2,2dimethoxypropane (8 mL) containing p-TsOH·H2O (80 mg, 0.42 mmol) was allowed to stand for 16 h at 25 °C, and diluted with EtOAc, which was washed with aqueous NaHCO3 and brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (1:1) gave 6a (635 mg, 56% yield) as a solid, mp 111-113 °C (from EtOAc-hexane). IR  $v_{max}$ (Nujol) 3380, 1750, 1640 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl3)  $\delta$  0.88 (3H, t, J=6.3-6.9 Hz), 1.05-1.33 (20H, m), 1.37 (3H, s), 1.49 (3H, s), 1.53 (2H, broad), 2.07-2.13 (2H, m), 2.56 (1H, bs, OH), 3.26 (1H, dt, J=5.5, 9.8 Hz), 3.58 (1H, t, J=8.9-9.6 Hz), 3.70 (1H, t, J=10.1-10.5 Hz), 3.78-3.87 (2H, m), 4.40 (1H, dt, J=5.9, 9.7 Hz, C3-H), 4.62 (1H, d, J=5.9 Hz, C2-H), 6.20 (1H, d, J=9.0 Hz, NH), 6.93 (1H, s), 7.32-7.39 (10H, m); MS (EI) *m*/z 623 (M<sup>+</sup>), 608 (M<sup>+</sup>-Me). *Anal.* Calcd. for C37H53NO7 (623.8): C, 71.24; H, 8.56; N, 2.25. Found: C, 71.32; H, 8.43; N, 2.27. Diphenylmethyl 2,6-Anhydro-3-deoxy-5,7-O-isopropylidene-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonate (7a). To a solution of 6a (624 mg, 1.00 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added (R)-3-(tetradecanoyloxy)tetradecanoic acid (546 mg, 1.20 mmol), DCC (248 mg, 1.20 mmol), and DMAP (146 mg, 1.20 mmol) with stirring at 24 °C. The mixture was stirred for 16 h at 25 °C, and diluted with EtOAc, which was washed with aqueous 0.1M HCl, water, aqueous NaHCO3 and brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (5:1) gave 7a (1.02 g, 96% yield) as a gum. IR  $v_{max}$ (film) 3310, 2925, 2860, 1730, 1655 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, J=6.4-6.9 Hz), 1.15-1.37 (61H, m), 1.45 (3H, s), 1.50-2.00 (7H, m, containing 3H singlet at  $\delta$  1.61), 2.20-2.30 (2H, m), 3.32-3.41 (1H, m), 3.65-3.84 (3H, m), 4.38-4.47 (1H, m), 4.67 (1H, d, J=6.1 Hz, C2-H), 5.14 (1H, t, J=6.3 Hz), 5.33 (1H, t, J=9.5-10.4 Hz), 6.08(1H, d, J=8.8 Hz, NH), 6.95 (1H, s), 7.30-7.37 (10H, m); MS (FAB, positive, addition of 1M KI aq solutiion) m/z 1098 (M+K)<sup>+</sup>. Anal. Calcd. for C65H105NO10 (1060.6): C, 73.61; H, 9.98; N, 1.32. Found: C, 73.64; H, 10.16; N, 1.49.

2,6-Anhydro-3-deoxy-3-tetradecanamido-4-0-[(R)-3-Diphenylmethyl (tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonate (8a). A suspension of 7a (1.00) g, 0.943 mmol) in aqueous 85% ACOH (100 mL) was stirred for 1 h at 70-75 °C, and the resulting solution was concentrated in vacuo with a pump, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (2:1, then 1:1) gave 8a (555 mg, 58% yield) as an amorphous solid, mp 105-106 °C (from hexane-cyclohexane). IR v<sub>max</sub>(Nujol) 3340, 1732, 1722 (shoulder), 1644 cm<sup>-1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.88 (9H, t, J=6.4-6.8 Hz), 1.26 (61H, bs), 1.40-1.50 (1H, m), 1.50-1.65 (2H, m), 1.96 (2H, t, J=7.3-8.1 Hz), 2.04 (1H, t, J=5.9 Hz, OH), 2.29 (2H, t, J=7.5 Hz), 2.50-2.54 (2H, m), 3.36 (1H, d, J=4.0 Hz, OH), 3.42-3.48 (1H, m), 3.66 (1H, dt, J=4.0, 9.3-9.7 Hz, changed to t, J=9.3-9.7 Hz, on addition of D<sub>2</sub>O), 3.73 (1H, m, changed to dd, J=4.0, 12.1 Hz, on addition of D<sub>2</sub>O), 3.81 (1H, m, changed to dd, J=3.2, 12.1 Hz, on addition of D<sub>2</sub>O), 4.37 (1H, m), 4.72 (1H, d, J=5.9 Hz, C<sub>2</sub>-H), 5.09 (1H, m), 5.23 (1H, dd, J=9.0, 11.0 Hz), 6.26 (1H, d, J=8.6 Hz, NH), 6.95 (1H, s), 7.29-7.39 (10H, m); MS (FAB, positive, addition of 1M KI aq solution) m/z 1058 (M+K)<sup>+</sup>. Anal. Calcd. for C62H101NO10 (1020.5): C, 72.97; H, 9.98; N, 1.37. Found: C, 72.62; H, 10.22; N, 1.42. H, 10.16; N, 1.49.

Diphenylmethyl 2,6-Anhydro-7-O-benzyloxycarbonyl-3-deoxy-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonate (9a). To a solution of 8a (200 mg, 0.196 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and pyridine (3.0 mL) was added dropwise ClCOOBn (1.6 mL) at 0-5 °C under nitrogen with stirring. After 30 min, the solution was concentrated in vacuo, and diluted with EtOAc, which was washed with aqueous 0.2M HCl, water, aqueous NaHCO3 and brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (4:1) gave 9a (219 mg, 97% yield) as a wax. IR  $v_{max}$ (film) 3550, 3290, 2920, 2840, 1730, 1652 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, J=6.2-7.0 Hz), 1.25 (61H, bs), 1.40-1.51 (1H, m), 1.51-1.65 (2H, m), 1.95 (2H, t, J=7.2-8.1 Hz), 2.28 (2H, t, J=7.4-7.6 Hz), 2.45-2.57 (2H, m), 3.34 (1H, d, J=3.8 Hz, OH), 3.53-3.67 (2H, m), 4.30-4.45 (3H, m), 4.71 (1H, d, J=6.0 Hz, C2-H), 5.08 (1H, m), 5.18 (1H, s), 5.21 (1H, m), 6.22 (1H, d, J=8.6 Hz, NH), 6.93 (1H, s), 7.21-7.38 (15H, m); MS (FAB, positive, addition of 1M KI aq solution) m/z 1192 (M+K)<sup>+</sup>. Anal. Calcd. for C70H107NO12 (1154.6): C, 72.82; H, 9.34; N, 1.21. Found: C, 72.60; H, 9.71; N, 1.27.

# Diphenylmethyl 2,6-Anhydro-7-O-benzyloxycarbonyl-3-deoxy-5-O-diphenylphosphono-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetra-decanoyl]-D-glycero-D-ido-heptonate

(10a). To a solution of 9a (174 mg, 0.15 mmol) and DMAP (42 mg, 0.344 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 ml) was added dropwise diphenyl chlorophosphate (90 mg, 0.335 mmol). After stirring at 24 °C for 4 h, the reaction mixture was diluted with EtOAc, washed with aqueous 1M HCl, water, aqueous NaHCO<sub>3</sub>, and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to give a residue, which was chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (4:1) gave 10a (182 mg, 87% yield) as an amorphous solid. IR v<sub>max</sub>(Nujol) 3340, 1737, 1660 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, J=6.5-6.8 Hz), 1.25 (61H, bs), 1.37-1.57 (3H, m), 1.80-1.97 (2H, m), 2.16 (1H, t, J=7.2-7.8 Hz), 2.33-2.48 (2H, m), 3.90 (1H, dm, J=7.9, <1 Hz), 4.09 (1H, dd, J=4.3, 12.1 Hz), 4.23 (1H, dd, =2.0, 12.1 Hz), 4.37-4.47 (1H, m), 4.70 (1H, q, J=9.2 Hz), 4.81 (1H, d, =6.0 Hz), 5.01, 5.10 (2H, AB-q, J=12.0 Hz), 5.07 (1H, m), 5.55 (1H, dd, J=8.9, 11.0 Hz), 6.11 (1H, d, J=7.9 Hz, NH), 6.94 (1H, s), 7.11-7.39 (25H, m); MS (FAB, positive, addition of 1M KI aq solution) *m/z* 1424 (M+K)<sup>+</sup>. *Anal.* Calcd. for C8<sub>2</sub>H<sub>116</sub>NO<sub>15</sub>P (1386.8): C, 71.02; H, 8.43; N, 1.01; P, 2.23. Found: C, 70.77; H, 8.63; N, 0.99; P, 2.32.

2,6-Anhydro-3-deoxy-5-O-diphenylphosphono-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonic Acid (11a). To a solution of 10a (159 mg, 0.115 mmol in THF, 4 mL) was added 10% Pd on carbon (115 mg), and the mixture was stirred for 10 h under hydrogen at 25 °C, and the whole was filtered. The filtrate was concentrated in vacuo, and chromatographed on a silica gel column. Elution with EtOAc, and then with 2% AcOH in EtOAc gave 11a (111 mg, 89% yield) as an amorphous solid. IR  $v_{max}$ (Nujol) 3700-3000, 1733, 1660 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, J=6.4-6.7 Hz), 1.24 (61H, bs), 1.37-1.60 (3H, m), 2.08-2.17 (4H, m), 2.38 (1H, d, J=6.2 Hz), 2.71 (1H, bs, OH), 3.58 (1H, m), 3.66-3.83 (2H, m), 4.43-4.73 (3H, m), 5.10 (1H, m), 5.50-5.63 (1H, m), 6.50-6.65 (1H, broad, NH), 7.17-7.37 (10H, m); MS (FAB, positive) m/z 1108 (M+Na)<sup>+</sup>. Anal. Calcd. for C61H100NO13P (1086.4): C, 67.44; H, 9.28; N, 1.29; P, 2.85. Found: C, 67.49; H, 9.28; N, 1.30; P, 2.79.

#### 2,6-Anhydro-3-deoxy-5-O-phosphono-3-tetradecanamido-4-O-[(R)-3-

(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonic Acid (12a). A solution of 11a (91 mg, 0.084 mmol) in THF (4 ml) was stirred for 3 h at 25 °C under hydrogen using PtO<sub>2</sub> (22 mg) as a catalyst. The reaction mixture was filtered, and the filtrate was concentrated in vacuo to give 12a (72 mg, 92% yield) as an amorphous solid. IR  $v_{max}$ (Nujol) 3360 (broad), 1735, 1650 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, *J*=6.0-6.8 Hz), 1.26 (58H, bs), 1.57 (6H, m), 2.10-2.80 (6H, m), 3.60-4.10 (3H, m), 4.20-4.70 (3H, m), 5.06-5.40 (2H, m), 7.00 (1H, bs, NH); MS (FAB, positive) *m*/z 956 (M+Na)<sup>+</sup>, 935 (M+H)<sup>+</sup>. Anal. Calcd. for C49H92NO<sub>13</sub>P (934.2): C, 63.00; H, 9.93; N, 1.50; P, 3.32. Found: C, 63.13; H, 9.87; N, 1.18; P, 3.11.

2,6-Anhydro-3-[(R)-3-(benzyloxy)tetradecanamido]-4-O-[(R)-3-(benzyloxy)tetradecanoyl]-3-deoxy-5,7-O-isopropylidene-D-glycero-D-ido-heptononitrile (4b). To a solution of 3 (1.19 g, 4.68 mmol) in THF (47 mL) was added Ph3P (2.46 g, 9.36 mmol). After stirring for 3 h at 24 °C, H2O (4.7 mL) was added to this solution. The mixture was stirred for 16 h at 24 °C, concentrated in vacuo, diluted with EtOAc, and concentrated in vacuo again. This procedure was repeated 3 times to remove the water completely. The residual mixture was dissolved in THF (47 mL). To this solution, (R)-3-(benzyloxy)tetradecanoic acid (1.72 g, 5.15 mmol), DCC (1.06 g, 5.15 mmol), and DMAP (629 mg, 5.15 mmol) were added with stirring at 24 °C. After 3 h, to this reaction mixture, (R)-3-(benzyloxy)tetradecanoyl chloride, which was obtained from the corresponding acid (1.72 g, 5.15 mmol) and excess oxalyl chloride in CH2Cl2, and Et3N (1.5 mL, 10.8 mmol) were added at 24 °C with stirring. The stirring was continued for 16 h at 24 °C. The reaction mixture was filtered, and the filtrate was diluted with EtOAc, which was washed with H2O, aqueous NaHCO3, and brine, dried over MgSO4, filtered, and concentrated in vacuo to give a mixture. The mixture was chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (9:1, then 4:1) gave 4b (3.44 g, 85% yield) as an amorphous solid. IR  $v_{max}$ (film) 3280, 2920, 2860, 1738, 1652 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.88 (6H, t, J=6.3-6.9 Hz), 1.25 (36H, bs), 1.33 (3H, s), 1.42 (3H, s), 1.52 (4H, bm), 2.27-2.44 (2H, m), 2.45 (1H, dd, J=5.7, 15.1 Hz), 2.65 (1H, dd, J=6.6, 15.1 Hz), 3.68-3.85 (5H, m), 3.92-3.97 (1H, m), 4.26 (1H, dt, J=10.8, 6.4 Hz), 4.45, 4.58 (2H, AB-q, J=11.9 Hz), 5.08 (1H, d, J=6.1 Hz), 5.20 (1H, dd, J=8.8, 10.5 Hz), 6.79 (1H, d, J=6.8 Hz, NH), 7.27-7.40 (10H, m); Anal. Calcd. for C52H80N2O8 (861.2): C, 72.51; H, 9.37; N, 3.25. Found: C, 72.38; H, 9.44; N, 3.28.

2,6-Anhydro-3-deoxy-5,7-O-isopropylidene-3-[(R)-3-(benzyloxy)tetra-decanamido]-Dglycero-D-ido-heptononitrile (13b). Compound 3 was treated as described in the formation of 13a using (R)-3-(benzyloxy)tetradecanoic acid in place of tetradecanoic acid to give 13b in 49% yield.

Diphenylmethyl 2,6-Anhydro-3-[(R)-3-(benzyloxy)tetradecanamido]-3-deoxy-Dglycero-D-ido-heptonate (5b). (a) A solution of 4b (3.44 g, 3.99 mmol) in dioxane (22 mL), 4M HCl in dioxane (22 mL), and H2O (2.2 mL) was warmed at 60-65 °C (bath temperature) for 5 h. The mixture was concentrated in vacuo, diluted with EtOAc, and concentrated. This procedure was repeated 3 times to remove the water completely, and the residue was dissolved in DMF (30 mL). Ph<sub>2</sub>CN<sub>2</sub> (2.00 g, 10.3 mmol) was added to this solution, which was warmed at 55-60 °C for 1 h, concentrated in vacuo, and chromatographed on a silica gel column. Elution with EtOAc, then 5% MeOH in EtOAc gave **5b** (897 mg, 33% yield) as an amorphous solid. IR  $\nu_{max}$ (Nujol) 3330, 1735, 1640 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl3)  $\delta$  0.88 (3H, t, J=6.4-6.7 Hz), 1.20-1.60 (22H, m), 1.92-2.08 (2H, m), 3.44 (1H, m), 3.60-3.80 (3H, m), 3.80-3.92 (1H, m), 3.92-4.07 (1H, m), 4.53 (1H, m, OH), 4.80 (1H, d, J=5.9 Hz), 5.00 (1H, bs, OH), 5.11 (1H, bs, OH), 6.85 (1H, s), 7.25-7.47 (10H, m), 7.57 (1H, d, J=7.3 Hz, NH); MS (FAB, positive) m/z 712 (M+Na)<sup>+</sup>. Anal. Calcd. for C41H55NO8 (689.9): C, 71.37; H, 8.04; N, 2.03. Found: C, 71.25; H, 8.17; N, 2.01.

(b) Compound 13b was treated as described in the formation of 5a from 13a to give 5b in 41% yield.

**Diphenylmethyl** 2,6-Anhydro-3-[(R)-3-(benzyloxy)tetradecanamido]-3-deoxy-5,7-0isopropylidene-D-glycero-D-ido-heptonate (6b). A solution of 5b (897 mg, 1.30 mmol) in DMF (4 mL) and 2,2-dimethoxypropane (8 mL) containing p-TsOH-H2O (100 mg, 0.526 mmol) was allowed to stand for 16 h at 25 °C, and diluted with EtOAc, which was washed with aqueous NaHCO3 and brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (3:2) gave **6b** (422 mg, 44% yield) as an amorphous solid. IR  $v_{max}$ (Nujol) 3380, 1727, 1640 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (3H, t, J=6.4-6.8 Hz), 1.23-1.29 (18H, m), 1.36-1.65 (8H, m, containing two 3H, s, at  $\delta$  1.37 and 1.48), 2.29-2.44 (2H, m), 2.54 (1H, d, J=2.8 Hz, OH), 3.17-3.26 (1H, m), 3.56 (1H, t, J=9.3 Hz), 3.62-3.86 (4H, m), 4.35-4.51 (3H, m, containing 1H, d, J=5.9 Hz, at  $\delta$  4.41), 4.56 (1H, d, J=5.9 Hz), 6.83 (1H, d, J=6.9 Hz, NH), 6.84 (1H, s), 7.24-7.38 (15H, m); MS (EI) *m*/z 729 (M<sup>+</sup>). Anal. Calcd. for C44H59NO8 (730.0): C, 72.40; H, 8.15; N, 1.92. Found: C, 71.95; H, 7.85; N, 2.22.

# Diphenylmethyl 2,6-Anhydro-3-[(R)-3-(benzyloxy)tetradecanamido]-3-deoxy-5,7-Oisopropylidene-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonate (7b).

To this solution of **6b** (422 mg, 0.578 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) was added (R)-3-(tetradecanoyloxy)tetradecanoic acid (289 mg, 0.636 mmol), DCC (140 mg, 0.679 mmol), and DMAP (83 mg, 0.679 mmol) was added with stirring at 24 °C. The mixture was stirred for 16 h at 25 °C, and filtered. The filtrate was diluted with EtOAc, which was washed with aqueous 0.1M HCl, water, aqueous NaHCO3 and brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (5:1) gave 7b (583 mg, 86% yield) as a wax. IR v<sub>max</sub>(film) 3400, 2930, 2860, 1736, 1660 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl3)  $\delta$  0.88 (9H, t, J=6.3-6.8 Hz), 1.25 (60H, s), 1.30 (3H, s), 1.35-1.84 (7H, m, containing 3H, s, at  $\delta$  1.44), 2.13-2.31 (4H, m), 2.46 (1H, dd, J=6.2, 15.3 Hz), 2.60 (1H, dd, J=6.7, 15.6 Hz), 3.27 (1H, td, J=4.2-5.5, 14.0 Hz), 3.63-3.81 (5H, m), 4.37 (2H, s), 4.48 (1H, m), 4.60 (1H, d, J=5.9 Hz, C2-H), 5.35 (1H, t, J=9.6-10.3 Hz), 6.55 (1H, d, J=8.8 Hz, NH), 6.85 (1H, s), 7.25-7.40 (15H, m); MS (FAB, positive) *m/z* 1166 (M+H)<sup>+</sup>. Anal. Calcd. for C72H111NO11 (1166.7): C, 74.12; H, 9.59; N, 1.20. Found: C, 74.10; H, 9.63; N, 1.18.

Diphenylmethyl 2,6-Anhydro-3-[(R)-3-(benzyloxy)tetradecanamido]-3-deoxy-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonate (8b). A suspension of 7 (152 mg, 0.13 mmol) in aqueous 85% AcOH (16 mL) was stirred for 1 h at 70-75 °C, and the resulting solution was concentrated in vacuo with a pump, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (5:3) gave the starting 7b (60 mg recovery, 39%), a lower Rf isomer (19 mg, 13%) of 8b, and 8b (55 mg, 58% yield) as an amorphous solid, mp 93-94 °C (from hexane-EtOAc). IR v<sub>max</sub>(Nujol) 3420 (shoulder), 1730, 1648 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl3)  $\delta$  0.88 (9H, t, J=6.4-6.8 Hz), 1.25 (61H, bs), 1.41-1.62 (3H, m), 2.21-2.32 (4H, m), 2.45-2.49 (2H, m), 3.30 (1H, d, J=4.0 Hz, OH), 3.38 (1H, dt, J=9.6, 3.8 Hz), 3.58-3.84 (4H, m), 4.38 (2H, s), 4.43 (1H, m), 5.24 (1H, dd, J=9.0, 11.0 Hz), 6.66 (1H, d, J=8.7 Hz, NH), 6.85 (1H, s), 7.23-7.39 (15H, m); MS (FAB, positive) m/z 1126 (M+H)<sup>+</sup>, 1148 (M+Na)<sup>+</sup>. Anal. Calcd. for C69H107NO11 (1126.6): C, 73.56; H, 9.57; N, 1.24. Found: C, 73.48; H, 9.51; N, 1.30.

Diphenylmethyl2, 6 - Anhydro-7 - O - benzyloxycarbonyl-3 - [(R) - 3 - [(R) - 3 - [(B) - [(B) - 3 - [(B) -

solution was washed with aqueous 0.2M HCl, water, aqueous NaHCO3 and brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (9:1, then 4:1) gave 9b (217 mg, 97% yield) as a wax. IR  $v_{max}$ (Nujol) 3525, 3310, 1735, 1648 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl3)  $\delta$  0.88 (9H, t, J=6.4-6.8 Hz), 1.25 (61H, bs), 1.50-1.63 (3H, m), 2.15-2.31 (4H, m), 2.41-2.54 (2H, m), 3.35 (1H, bs, OH), 3.55 (2H, bs), 3.67 (1H, quintet, J=5.3-5.8 Hz), 4.29-4.50 (5H, m, containing 2H, s, at 5 4.38), 4.64 (1H, d, J=5.9 Hz, C2-H), 5.06 (1H, m), 5.14-5.26 (3H, m, containing 2H, s, at  $\delta$  5.18), 5.21 (1H, m), 6.65 (1H, d, J=8.8 Hz, NH), 6.83 (1H, s), 7.22-7.40 (20H, m); MS (FAB, positive) *m/z* 1260 (M+H)<sup>+</sup>, 1282 (M+Na)<sup>+</sup>. Anal. Calcd. for C77H113NO13 (1260.7): C, 73.36; H, 9.03; N, 1.11. Found: C, 73.18; H, 9.31; N, 1.14.

# Diphenylmethyl 2,6-Anhydro-7-O-benzyloxycarbonyl-3-[(R)-3-(benzyloxy)tetradecanamido]-3-deoxy-5-O-diphenylphosphono-4-O-[(R)-3-

(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonate (10b). To a solution of 9b (207 mg, 0.04 mmol) and diphenyl chlorophosphate (144 mg, 0.164 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (12 mL) was added DMAP (80 mg, 0.655 mmol). After stirring at 24 °C for 2 h, the reaction mixture was concentrated in vacuo, and diluted with EtOAc, The solution was washed with aqueous 1M HCl, water, aqueous NaHCO<sub>3</sub>, and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to give a residue, which was chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (5:1) gave 10b (223 mg, 91% yield) as an oil. IR v<sub>max</sub>(film) 3440, 2930, 2850, 1750 (shoulder), 1730, 1670, 1590 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, J=6.6-7.0 Hz), 1.25 (60H, bs), 1.25-1.60 (4H, m), 2.11-2.26 (4H, m), 2.41 (1H, d, J=6.3 Hz), 3.73 (1H, t, J=5.3-6.4 Hz), 3.75 (1H, td, J=2.1, 11.7 Hz), 4.08 (1H, dd, J=4.4, 12.0 Hz), 4.21 (1H, dd, J=1.8, 12.0 Hz), 4.37 (2H, s), 4.49 (1H, m), 4.67 (1H, t, J=9.2 Hz), 4.71 (1H, d, J=5.7 Hz, C2-H), 5.01, 5.10 (2H, AB-q, =12.1 Hz), 5.08 (1H, m), 5.56 (1H, dd, J=9.0, 11.0 Hz), 6.57 (1H, d, J=8.3 Hz, NH), 6.83 (1H, s), 7.10-7.41 (30H, m); MS (FAB, positive) m/z 1492 (M+H)<sup>+</sup>, 1514 (M+Na)<sup>+</sup>. Anal. Calcd. for C89H122NO16P (1492.9): C, 71.60; H, 8.24; N, 0.94; P, 2.07. Found: C, 71.48; H, 8.41; N, 0.90; P, 2.18.

2,6-Anhydro-3-deoxy-5-O-diphenylphosphono-3-[(R)-3-(hydroxy)tetradecan-amido]-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonic Acid (11b). To a solution of 10b (49 mg, 0.03 mmol) in EtOAc (4 mL) was added 10% Pd on carbon (50 mg), and the mixture was stirred for 18 h under hydrogen at 25 °C, and then filtered. The filtrate was concentrated in vacuo, and chromatographed on a silica gel short column. Elution with EtOAc, and then with 3% AcOH in EtOAc gave 11b (27 mg, 75% yield) as an amorphous solid. IR  $v_{max}$ (Nujol) 3360, 2930, 2850, 1735, 1640, 1600 (shoulder) cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl3)  $\delta$  0.88 (9H, t, J=6.1-6.9 Hz), 1.25 (60H, bs), 1.30-1.60 (4H, m), 2.1-2.41 (6H, m), 3.58 (1H, dd, J=2.6, 13.0 Hz), 3.72 (1H, d, J=13.0 Hz), 3.84-4.00 (2H, m), 4.52 (1H, m), 4.69-4.79 (2H, m), 5.10 (1H, m), 5.60 (1H, t, J=9.9 Hz), 7.05 (1H, d, J=8.7 Hz, NH), 7.08-7.38 (10H, m); MS (FAB, positive) m/z 1102 (M+H)<sup>+</sup>. Anal. Calcd. for C61H1003NO13P (1102.4): C, 66.44; H, 9.15; N, 1.27; P, 2.81. Found: C, 66.31; H, 9.28; N, 1.27; P, 2.81.

2,6-Anhydro-3-deoxy-5-O-phosphono-3-[(R)-3-(hydroxy)tetradecanamido]-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonic Acid (12b). A solution of 11b (23 mg, 0.02 mmol) in THF (3 mL) was stirred for 6 h at 25 °C under hydrogen using PtO2 (25 mg) as a catalyst. The reaction mixture was filtered, and the filtrate was concentrated in vacuo to give 12b (19 mg, 96% yield) as a powder. IR  $v_{max}$ (Nujol) 3360 (broad), 1720, 1638 cm<sup>-1</sup>; <sup>1</sup>H-NMR (pyridine-d5)  $\delta$  0.86-0.91 (9H, m), 1.26 (52H, bs), 1.27-1.60 (3H, m), 1.63-1.88 (10H, m), 2.46 (2H, t, J=7.5 Hz), 2.79 (1H, d, J=1.1 Hz), 2.81 (1H, s), 3.13 (1H, dd, J=6.3, 15.9 Hz), 3.26 (1H, dd, J=6.5, 15.9 Hz), 4.20 (1H, d, J=9.1 Hz), 4.45-4.52 (3H, m), 5.11 (1H, d, J=5.9 Hz, C2-H), 5.26-5.34 (2H, m), 5.71-5.74 (1H, m), 6.52 (1H, dd, J=9.2, 10.7 Hz), 8.68 (1H, d, J=9.3 Hz, NH); MS (FAB, positive) m/z 972 (M+Na)<sup>+</sup>, 950 (M+H)<sup>+</sup>; MS (FAB, negative) 948 (M-H)<sup>-</sup>. Anal. Calcd. for C49H92NO13P (950.2): C, 61.94; H, 9.76; N, 1.47; P, 3.26. Found: C, 61.25; H, 9.88; N, 1.34; P, 3.17.

Diphenylmethyl 2,6-Anhydro-3-deoxy-5-O-diphenylphosphono-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonate (14). A solution of 10a (260 mg, 0.187 mmol) in THF (30 mL) containing 10% Pd on carbon (300 mg) was stirred vigorously under hydrogen at 24 °C for 10 h. After filtration, Ph<sub>2</sub>CN<sub>2</sub> (200 mg, 1.03 mmol) was added to this solution, and the mixture was stirred for 16 h at 24 °C, concentrated in vacuo, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (2:1) gave 14 (235 mg, 100%) as a gum. IR  $v_{max}$ (film) 3600-3200, 2925, 2850, 1735, 1658, 1590 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, J=6.2-6.9 Hz), 1.25 (56H, bs), 1.35-1.72 (8H, m), 1.90-1.99 (2H, m), 2.19 (2H, t, J=7.4-7.7 Hz), 2.34-2.37 (2H, m), 3.19 (1H, bs, OH), 3.38-3.59 (3H, m), 4.47 (1H, m), 4.73 (1H, q, J=9.5 Hz), 4.80 (1H, d, J=6.0 Hz), 5.10 (1H, quintet, J=6.1 Hz), 5.60 (1H, dd, J=9.4, 10.8 Hz), 6.12 (1H, d, J=8.3 Hz, NH), 6.94 (1H, s), 7.10-7.38 (20H, m); MS (FAB, positive) m/z 1251 (M<sup>+</sup>)°, 1274 (M+Na)<sup>+</sup>. Anal. Calcd. for C74H110NO13P (1252.7): C, 70.95; H, 8.85; N, 1.12; P, 2.47. Found: C, 70.59; H, 8.70; N, 1.28; P, 3.00.

Diphenylmethyl 2,6-Anhydro-3,7-dideoxy-5-O-diphenylphosphono-7-fluoro-3tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonate

(15). To a solution of 14 (251 mg, 0.20 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added dropwise a solution of DAST (1.29 g, 8.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) at 0-5°C with stirring. After stirring for 3.5 h at 0 °C, the reaction mixture was diluted with EtOAc, washed with aqueous NaHCO<sub>3</sub>, and brine, dried over MgSO<sub>4</sub>, filtered, concentrated in vacuo, and chromatographed on a silica gel column. Elution with cyclohexane-EtOAc (4:1) gave 15 (218 mg, 87%) as a gum. IR  $\nu_{max}$ (Nujol) 3340 (w), 1738, 1663, 1590 (w) cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, *J*=6.4-6.8 Hz), 1.25 (60H, bs), 1.35-1.60 (4H, m), 1.80-2.00 (2H, m), 2.16 (2H, t, *J*=7.4-7.7 Hz), 2.33-2.50 (2H, m), 3.85 (1H, dd, *J*=9.9, 24.6 Hz), 4.37-4.48 (2H, m), 4.68 (1H, dd, *J*=9.2, 18.7 Hz), 4.86 (1H, d, *J*=6.0 Hz), 5.08 (1H, m), 5.58 (1H, dd, *J*=8.9, 11.0 Hz), 6.11 (1H, d, *J*=7.9 Hz, NH), 6.96 (1H, s), 7.12-7.41 (20H, m); MS (FAB, positive) *m/z* 1254 (M+H)<sup>+</sup>; High Resolution MS (FAB, positive) *m/z*: Calcd. for C74H110NO12FP: 1254.7750; Found: 1254.7793; *Anal.* Calcd. for C74H109NO12FP (1254.7): C, 70.84; H, 8.76; N, 1.12; F, 1.51; P, 2.47. Found: C, 70.58; H, 8.46; N, 1.18; F, 1.33; P, 2.45.

2,6-Anhydro-3,7-dideoxy-5-O-diphenylphosphono-7-fluoro-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonic Acid (16). A solution of 15 (187 mg, 0.149 mmol) in THF (40 mL) containing 10% Pd on carbon (700 mg) was stirred for 18 h at 24 °C. The reaction mixture was filtered, and concentrated in vacuo to give 167 mg of a mixture of 16 and Ph<sub>2</sub>CH<sub>2</sub>. This mixture was pure enough for the next hydrogenolysis. However, when short column chromatography was performed, a fair amount of the carboxylic acid was absorbed. Elution with EtOAc-MeOH (95:5) gave pure 16 (107 mg, 66%) as a gum. IR  $v_{max}$ (film) 3380, 1736, 1680, 1640, 1590 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, J=5.8-7.0 Hz), 1.10-1.70 (64H, m, containing bs at  $\delta$  1.25), 2.14-2.20 (4H, m), 2.39-2.50 (2H, m), 4.22-4.60 (4H, m), 4.66 (1H, d, J=6.0 Hz), 4.74 (1H, dd, J=8.9, 17.5 Hz), 5.09 (1H, quintet, J=6.0 Hz), 5.63 (1H, dd, J=9.0, 10.9 Hz), 6.65 (1H, d, J=8.9 Hz, NH), 7.14-7.38 (10H, m); MS (FAB, positive) m/z 1110 (M+Na)<sup>+</sup>; High Resolution MS (FAB, positive) m/z: Calcd. for C61H99NO12FPNa: 1110.6785; Found: 1110.6770. Anal. Calcd. for C61H99NO12FP (1088.4): C, 67.31; H, 9.17; N, 1.29; F, 1.75; P, 2.85. Found: C, 67.01; H, 9.01; N, 1.29; F, 1.80; P, 2.69.

## 2,6-Anhydro-3,7-dideoxy-7-fluoro-5-O-phosphono-3-tetradecanamido-4-O-[(R)-3-

(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonic Acid (17). A solution of 16 (16 mg, 0.015 mmol) in THF (3 mL) containing PtO<sub>2</sub> (22 mg) was hydrogenolized with stirring for 17 h at 24 °C, filtered, and concentrated in vacuo to give 17 (14 mg, quantitatively) as an amorphous solid. IR  $v_{max}$ (Nujol) 3570, 3350, 3000-2500 (broad), 1742, 1727, 1710 (shoulder), 1654 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, J=6.1-7.0 Hz), 1.26 (58H, bs), 1.50-1.63 (6H, m), 2.16-2.25 (2H, m), 2.27-2.32 (2H, m), 2.55-2.75 (2H, m), 3.89 (1H, m), 4.31-4.50 (2H, m), 4.58-4.61 (2H, m), 4.76 (1H, bs), 5.12 (1H, m), 5.36 (1H, m), 6.91 (1H, d, J=9.5 Hz, D<sub>2</sub>O exchanged, NH); MS (FAB, positive) *m/z* 958 (M+Na)<sup>+</sup>; MS (FAB, negative) *m/z* 934 (M-H)<sup>-</sup>; High Resolution MS (FAB, positive) *m/z*: Calcd. for C49H91NO12FPNa: 958.6102; Found: 958.6132. Anal. Calcd. for C49H91NO12FP (936.2): C, 62.86; H, 9.80; N, 1.50; F, 2.03; P, 3.31. Found: C,62.55; H, 9.68; N, 1.32; F, 1.87; P, 3.01.

## 2,6-Anhydro-7-O-benzyloxycarbonyl-3-deoxy-5-O-diphenylphosphono-3-

tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonic Acid (18). A solution of 10a (65 mg, 0.047 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) and CF<sub>3</sub>COOH (0.20 mL, 2.60 mmol) was stirred for 2 h at 0-5 °C. To this reaction mixture, was added powdered NaHCO<sub>3</sub> (218 mg, 2.60 mmol) and H<sub>2</sub>O (2 mL), and diluted with EtOAc, which was washed with H<sub>2</sub>O and brine, dried over MgSO<sub>4</sub>, filtered, concentrated and chromatographed on a silica gel column. Elution with EtOAc, and then EtOAc-MeOH (95:5) gave fractions of product, which were concentrated in vacuo, and diluted with EtOAc, washed with H<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to give 18 (32 mg, 56%) as a gum. IR v<sub>max</sub>(film) 3400 (broad), 2935, 2860, 1750, 1660 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, J=5.7-6.9 Hz), 1.24 (58H, bs), 1.37-1.59 (6H, m), 2.07-2.19 (4H, m), 2.38-2.44 (2H, m), 4.10 (1H, m), 4.26-4.55 (4H, m), 4.68 (1H, dd, J=9.5, 18.8 Hz), 5.02-5.17 (3H, m), 5.59 (1H, m), 6.84 (1H, broad, NH), 7.10-7.33 (15H, m); MS (FAB, positive) m/z 1242 (M+Na)<sup>+</sup>. Anal. Calcd. for C<sub>69</sub>H<sub>106</sub>NO<sub>15</sub>P (1220.6): C, 67.90; H, 8.75; N, 1.15; P, 2.54. Found: C, 67.65; H, 8.70; N, 1.13; P, 2.68.

## Diphenylmethyl 2,6-Anhydro-7-O-[2,6-anhydro-7-O-benzyloxycarbonyl-3-deoxy-5-Odiphenylphosphono-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyl-oxy)tetradecanoyl]-Dglycero-D-ido-heptonyl]-3-deoxy-3-tetradecanamido-4-O-[(R)-3-

(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonate (19). To a solution of acid 18 (183 mg, 0.15 mmol) and diol 8a (30 mg, 0.02 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (8 mL) were added DMAP (18.3 mg, 0.15 mmol) and DCC (39 mg, 0.19 mmol) under nitrogen with stirring at 24 °C. After stirring for 16 h, the mixture

was concentrated in vacuo, and chromatographed on a preparative silica gel plate. Development with cyclohexane-EtOAc (3:1) gave 19 (35 mg, 11%,  $R_f$ =0.364) as a gum and 19' (46 mg, 22%,  $R_f$ =0.509) as a gum. Physical data of 19: IR v<sub>max</sub>(film) 3320, 2930, 2850, 1740, 1657, 1626 (w), 1590 (w) cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (18H, t, J=6.4-6.8 Hz), 1.25 (120H, bs), 1.37-1.61 (8H, m), 1.92 (2H, t, J=7.3-8.2 Hz), 2.05 (2H, t, J=7.3-8.2 Hz), 2.19 (2H, t, J=7.5-7.7 Hz), 2.27 (2H, t, J=7.4-7.7 Hz), 2.45-2.60 (4H, m), 3.69 (2H, bs), 3.91 (1H, bs, OH), 4.20-4.54 (7H, m), 4.69-4.75 (3H, m), 5.03-5.23 (5H, m, containing 2H, AB-q, J=12.3 Hz at  $\delta$  5.05 and 5.11), 5.43 (1H, t, J=7.5-8.2 Hz), 6.22 (1H, d, J=8.3 Hz, NH), 6.38 (1H, d, J=9.0 Hz, NH), 6.93 (1H, s), 7.15-7.36 (25H, m); MS (FAB, positive) *m/z* 2222 (M+H)<sup>+</sup>, 2221; *Anal.* Calcd. for C1<sub>31</sub>H<sub>205</sub>N<sub>2</sub>O<sub>24</sub>P (2223.0): C, 70.78; H, 9.30; N, 1.26. Found: C, 71.50; H, 8.71; N, 1.34. <sup>1</sup>H-NMR of 19': (CDCl<sub>3</sub>)  $\delta$  0.88 (9H, t, J=6.3-6.9 Hz), 1.25 (58H, bs), 1.39-1.97 (26H, m), 2.06-2.17 (4H, m), 2.38-2.42 (2H, m), 3.60 (1H, m), 3.82 (1H, m), 3.97-4.16 (2H, m), 4.40-4.63 (3H, m), 4.77 (1H, d, J=5.9 Hz, C2-H), 5.10 (2H, s), 5.10 (1H, m), 5.95 (1H, t, J=9.5-9.9 Hz), 6.13 (1H, d, J=8.9 Hz, NH), 7.15-7.40 (16H, m); MS (FAB, positive) *m/z* 1426 (M+H)<sup>+</sup>, 1448 (M+Na)<sup>+</sup>.

# 2,6-Anhydro-7-O-[2,6-anhydro-3-deoxy-5-O-diphenylphosphono-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyl)tetradecanoyl]-D-glycero-D-ido-heptonyl]-3-deoxy-3tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetra-decanoyl]-D-glycero-D-ido-heptonic

Acid (20). Hydrogenolysis of 19 (51 mg, 0.023 mmol) in THF (8 mL) containing 10% Pd on carbon (32 mg) for 6 h at 24 °C under hydrogen gave 20 (46 mg, containing Ph<sub>2</sub>CH<sub>2</sub>) as a gum after filtration and concentration. This mixture was pure enough, and employed for the next reaction without further purification. For analytical sample, the mixture (11 mg) was partly chromatographed to remove Ph<sub>2</sub>CH<sub>2</sub> on a silica gel short column. Elution with EtOAc-MeOH (95:5) gave 4 mg of 20. Most of 20 was absorbed on a silica gel column. IR  $v_{max}$ (film) 3380 (broad), 2925, 2850, 1735, 1650, 1590 (w) cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (18H, t, *J*=6.3-6.8 Hz), 1.25 (120H, bs), 1.43-1.63 (8H, m), 1.89-2.57 (12H, m), 3.42 (1H, t, *J*=9.0 Hz), 3.52-3.70 (3H, m), 3.80-3.94 (2H, m), 4.45 (2H, m), 4.55 (1H, m), 4.56-4.62 (2H, m), 4.72 (1H, m), 5.07-5.17 (2H, m), 5.26 (1H, t, *J*=9.0 Hz), 5.59 (1H, m), 6.44 (1H, d, *J*=9.2 Hz, NH), 6.52 (1H, d, *J*=7.4 Hz, NH), 7.14-7.39 (20H, m); MS (FAB, positive) *m*/*z* 1922, 1921 (M+H)<sup>+</sup>, 1828; High resolution MS (FAB, positive) *m*/*z*: Calcd. for C110H189N2O22PNa; 1944.3367. Found: 1944.3370. *Anal.* Calcd. for C110H189N2O22P (2223.0): C, 68.72; H, 9.91; N, 1.46; P, 1.61. Found: C, 68.20; H, 10.05; N, 1.82; P, 164.

# 2,6-Anhydro-7-O-[2,6-anhydro-3-deoxy-5-O-phosphono-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonyl]-3-deoxy-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonic Acid (21).

Hydrogenolysis of 20 (42 mg, above obtained and containing Ph<sub>2</sub>CH<sub>2</sub>) in THF (6 mL) containing PtO<sub>2</sub> (50 mg) as a catalyst at 24 °C for 16 h gave 40 mg of residue after concentration. The residue was dissolved in CHCl<sub>3</sub> (13 mL), MeOH (26 mL) and aqueous 0.1 M HCl (10.4 mL). To this solution, was added another volume of CHCl<sub>3</sub> (13 mL) and aqueous 0.1 M HCl (13 mL) to separate the solution into two phases. The lower CHCl<sub>3</sub> phase was collected and concentrated to give 21 (31 mg, 80%) as a foam. IR  $\nu_{max}$ (film) 3420, 2920, 2850, 2520, 1730, 1640 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (18H, t, J=6.4-6.8 Hz), 1.26 (114H, bs), 1.45-1.71 (14H, m), 2.10-2.24 (4H, m), 2.24-2.32 (4H, m), 2.52-2.68 (4H, m), 3.54 (1H, m), 3.74 (1H, m), 3.91 (2H, m), 4.00 (1H, m), 4.13 (1H, m), 4.35-4.51 (3H, m), 4.60 (1H, d, J=6.0), 4.69 (1

J=6.0), 4.93 (1H, m), 5.12 (2H, m), 5.22 (1H, m), 5.37 (1H, m), 6.71 (1H, broad, NH), 6.83 (1H, broad, NH); MS (FAB, positive) *m/z* 1791 (M+Na)<sup>+</sup>; High resolution MS (FAB, positive) *m/z*: Calcd. for C98H181N2O22PNa; 1792.2741. Found: 1792.2732. *Anal.* Calcd. for C110H189N2O22P (1770.5): C, 66.48; H, 10.31; N, 1.58; P, 1.75. Found: C, 66.72; H, 10.74; N, 1.75; P, 1.90.

Diphenylmethyl 2,6-Anhydro-7-O-[2,6-anhydro-3,7-dideoxy-5-O-diphenylphosphono-7-fluoro-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyl-oxy)tetradecanoyl]-D-glycero-D-idoheptonyl]-3-deoxy-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-Dglycero-D-ido-heptonate (22). To a solution of carboxylic acid 16 (96 mg, 0.088 mmol) and diol 8a (25 mg, 0.024 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL), were added DMAP (11 mg, 0.090 mmol) and DCC (22 mg, 0.107 mmol). The mixture was stirred for 16 h at 24 °C under nitrogen, filtered, and concentrated in vacuo to give a mixture, which was chromatographed on a preparative TLC plate. Development with cyclohexane-EtOAc (3:1) gave 22 (21 mg, 11%, Rf=0.500) as an amorphous solid. IR vmax(Nujol) 3360, 1737, 1725 (shoulder), 1657. 1632 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.88 (18H, t, J=6.3-6.9 Hz), 1.25 (112H, bs), 1.40-1.70 (16H, bm),1.91 (2H, t, J=7.3-7.8 Hz), 2.08 (2H, t, J=7.3-8.2 Hz), 2.17 (2H, t, J=7.4-7.8 Hz), 2.29 (2H, t, J=7.5 Hz), 2.45-2.54 (4H, m), 3.65-3.74 (2H, m), 4.10 (1H, dm, J=25 Hz), 4.25 (1H, dd, J=2.0, 10.0 Hz), 4.31-4.60 (5H, m), 4.66-4.76 (3H, m), 5.05-5.22 (3H, m), 5.49 (1H, dd, J=8.2, 9.4 Hz), 6.22 (1H, d, J=8.4 Hz, NH), 6.38 (1H, d, J=8.9 Hz, NH), 6.94 (1H, s), 7.16-7.21 (5H, m), 7.28-7.38 (15H, m); MS (FAB, positive) m/z 2090 (M+H)+; High resolution MS (FAB, positive) m/z: Calcd. for C123H199N2O21FP; 2090.4287. Found: 2090.4287.

2,6-Anhydro-7-O-[2,6-anhydro-3,7-dideoxy-5-O-diphenylphosphono-7-fluoro-3tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonyl]-3deoxy-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-idoheptonic Acid (23). Compound 22 (21 mg) was treated as described in the formation of 19 from 20 to give 23 (21 mg, quantitatively) as a gum. IR v<sub>max</sub>(film) 3380, 2920, 2850, 1737, 1675 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.88 (18H, t, J=5.9-7.2 Hz), 1.25 (112H, bs), 1.40-1.70 (16H, m), 2.10-2.23 (6H, m), 2.30 (2H, t, J=7.3-8.7 Hz), 2.43-2.62 (4H, m), 3.49 (1H, t, J=9.3 Hz), 3.70-3.92 (1H, m), 4.01-4.78 (10H, m), 5.06-5.19 (3H, m), 5.47 (1H, dd, J=8.6, 10.1 Hz), 6.60 (1H, d, J=8.7 Hz, NH), 6.66 (1H, d, J=8.5 Hz, D<sub>2</sub>O exchanged, NH), 7.14-7.34 (10H, m); MS (FAB, positive) m/z 1946 (M+Na)<sup>+</sup>; High resolution MS (FAB, positive) m/z: Calcd. for C110H188N2O21FPNa; 1946.3308. Found: 1946.3290.

## 2,6-Anhydro-7-O-[2,6-anhydro-3,7-dideoxy-7-fluoro-5-O-phosphono-3-

tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-ido-heptonyl]-3deoxy-3-tetradecanamido-4-O-[(R)-3-(tetradecanoyloxy)tetradecanoyl]-D-glycero-D-idoheptonic Acid (24). Compound 23 (20 mg) was treated as described in the formation of 21 from 20 to give 24 (18 mg, quantitatively) as a powder. IR  $v_{max}$ (Nujol) 3300-2500, 1733, 1654 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl3 + D<sub>2</sub>O)  $\delta$  0.88 (18H, t, J=6.4-6.8 Hz), 1.26 (112H, bs), 1.45-1.66 (16H, m), 2.10-2.25 (4H, m), 2.25-2.37 (4H, m), 2.45-2.74 (4H, m), 3.50 (1H, m), 3.60 (1H, t, J=9.4 Hz), 3.95-4.20 (3H, m), 4.28-4.42 (2H, m), 4.47- 4.52 (1H, m), 4.61-4.64 (2H, m), 4.81 (1H, m), 5.01-5.19 (3H, m), 5.23 (1H, dd, J=8.9, 11.7 Hz), 5.38 (1H, dd, J=8.9, 10.9 Hz), 6.68 (1H, broad before addition of D<sub>2</sub>O, NH), 6.92 (1H, broad before addition of D<sub>2</sub>O, NH); MS (FAB, positive) *m/z* 1772 (M+H)<sup>+</sup>, 1794 (M+Na)<sup>+</sup>; High resolution MS (FAB, positive) *m/z*: Calcd. for C98H181N2O21FP; 1772.2910. Found; 1772.2928. *Anal.* Calcd. for C98H180N2O21FP (1772.5): C, 66.41; H, 10.24; N, 1.58; F, 1.07; P, 1.75. Found: C, 65.94; H, 10.05; N, 1.76; F, 1.01; P, 1.72.

**Preparation of aqueous solutions of compounds for measurement of the biological activity.** Compound 12a (3.1 mg) obtained above was dissolved in CHCl3 (1 mL), MeOH (2 mL), and 0.1 M HCl (0.8 mL) with stirring at 5-10 °C. Additional CHCl3 (1 mL) and 0.1 M HCl (1 mL) were added to this solution to ensure separation into two phases. The lower chloroform phase was collected, and concentrated to give 3.0 mg of 12a, which was dissolved in 0.642 mL of aqueous 0.1% Et3N (v/v) solution for measurement of the biological activity. Aqueous 0.1% Et3N solutions of compounds 12b, 17, 21, and 24 were prepared as described above in the preparation of the solution of compound 12a.

**Procedures for measurement of the biological activity.** The sources of the materials used in the study are as follows: Lipopolysaccharide (LPS) from *E. coli* serotype 026:B6, 12-*O*tetradecanoylphorbor acetate (TPA) and prednisolone were from SIGMA, St. Louis, MO. PRMI-6140 medium, fetal bovine serum (FBS), and newborn calf serum (NBCS) were from GIBCO, Grand Island, NY. Human tumor necrosis factor- $\alpha$  enzyme-linked immunosorbent assay (TNF $\alpha$  ELISA) kit was from Genzyme, Cambridge, MA.

Cell culture: Human monoblastic U937 cells were maintained in RPMI-1640 medium supplemented with 10% FBS, 100 units/mL of penicillin and 100  $\mu$ g/mL of streptomycin (growth medium).

Production of TNF $\alpha$  by U937 cells: U937 cells (1 x 10<sup>4</sup>/200 µL/well) were plated in 96-well plates (Corning, Cambridge, MA), and were cultured in the presence of TPA (30 ng/mL) for 72 h at 37° C. After removing of the supernatant, the cell were incubated in 200 µL of fresh RPMI-1640 medium containing 10% of NBCS, 10 ng/mL of LPS and graded concentrations of compounds in a humidified atmosphere of 5% of CO<sub>2</sub> for 4.5 h at 37° C. After incubation, the amounts of TNF $\alpha$  produced in the culture supernatants were determined by the TNF $\alpha$  ELISA kits. As a control, the amount of TNF $\alpha$  produced by U937 cells, which were stimulated with 10 ng/mL of LPS in the absence of compounds, was used. The relative amounts of TNF $\alpha$  were calculated as percentages of the control amounts.

Acknowledgment. This study was supported, in part, by the Social Insurance Agency Fund commissioned by the Japan Health Sciences Foundation.

#### References

 a) H. Paulsen and C. Krognlann, Carbohydr. Res., 205, 31-44 (1990).
b) H. Paulsen and E. C. Hoffgen, Tetrahedron Lett., 32, 2747-2750 (1991).
c) H. Paulsen and M. Brenken, Liebigs Ann. Chem., 1991, 1113-1126.
d) E. Katzenellenbogen, A. Gamian, E. Romanowska, U. Dabrowski, and J. Dabrowski, Eur. J. Biochem., 196, 197-201 (1991).
e) M. B. Perry and M. M. MacLeen, Carbohydr. Res., 232, 143-150 (1992).

2. O. Westphal and O. Luderitz, Angew. Chem., 66, 407-417 (1954).

a) M. Imoto, H. Yoshimura, N. Sakaguchi, S. Kusumoto, and T. Shiba, *Tetrahedron Lett.*, 26, 1545-1548 (1985).
b) S. Takahashi, S. Nakamoto, K. Ikeda, and K. Achiwa, *Tetrahedron Lett.*, 27, 1819-1822 (1986).

4. a) M. Matsuura, Y. Kojima, J. Y. Homma, Y. Kubota, A. Yamamoto, M. Kiso, and A. Hasegawa, *FEBS Lett.*, **167**, 226-230 (1984). b) M. Kiso, H. Ishida, and A. Hasegawa, *Agric. Biol. Chem.*, **48**, 251-252 (1984). c) M. Kiso, S. Tanaka, M. Fujita, Y. Fujishima, Y. Ogawa, H. Ishida, and Hasegawa, *Carbohydr. Res.*, **162**, 127-140 (1987). d) M. Kiso, Y. Ogawa, S. Tanaka, Y. Fujishima, M. Fujita, S. Tanaka, and A. Hasegawa, *J. Carbohydr. Chem.*, **6**, 625-638 (1987).

5. a) N. Qureshi, J. P. Honovich, H. Hara, R. J. Cotter, and K. Takayama, J. Biol. Chem., 263, 5502-5504 (1988). b) N. Qureshi, K. Takayama, and R. Kurtz, Infect. Immunol., 59, 441-444 (1991).

6. W. J. Christ, O. Asano, A. L. C. Robidoux, M. Perez, Y. Wang, G. R. Dubuc, W. E. Gavin, L. D. Hawkins, P. D. McGuinness, M. A. Mullarkey, M. D. Lewis, Y. Kishi, T. Kawata, J. R. Bristol, J. R. Rose, D. P. Rossignol, S. Kobayashi, I. Hishinuma, A. Kimura, N. Asakawa, K. Katayama, and I. Yamatsu, *Science*, **268**, 80-83 (1995).

7. Y. Kobayashi, N. Ishida, M. Arai, M. Shiozaki, M. Arai, T. Hiraoka, M. Nishijima, S. Kuge, T. Otsuka, and Y. Akamatsu, Chem. Pharm. Bull., 40, 333-337 (1992).

8. M. Shiozaki, T. Mochizuki, T. Wakabayashi, S. Kurakata, T. Tatsuta, and M. Nishijima, *Tetrahedron Lett.*, 37, 7271-7274 (1996).

9. A. Vasella, C. Witzig, J-L. Chiara, and M. Martin-Romas, Helv. Chim. Acta, 74, 2073-2077 (1991).

10. G. Excoffier, D. Gagnaire, J-P. Utille, Carbohydr. Res., 39, 368-373 (1975).

11. M. G. Hoffmann and R. R. Schmidt, Liebigs Ann. Chem., 2403-2419 (1985).

12. C. Diolez, M. Mondange, S. R. Sarfati, L. Szabo, and P. Szabo, J. Chem. Soc. Perkin Trans. I, 275-280 (1984).

13. S. Heidenreich, D. Lang, M. Tepel, and K. M. Rahn, Transpl. Immunol., 2, 35-40 (1994).

(Received in Japan 22 July 1997; accepted 8 September 1997)